Depression treatment for Miami — measurement-based, 65 minutes away.

RECO Health's Delray Beach campus is roughly 65 minutes up I-95 from Brickell or Coral Gables — close enough for weekend family sessions, far enough to break the trigger geography that maintains depression in Miami's social scene. In-house psychiatry, measurement-based care with weekly PHQ-9 tracking, and same-campus access to rTMS, IV ketamine, and Spravato mean escalation happens on a defined schedule rather than after months of drift.

From Brickell, Coral Gables, or Coconut Grove, the drive to RECO Health’s Delray Beach campus runs about 50 miles up I-95 — roughly 65 minutes outside of peak traffic. For most Miami clients presenting with moderate-to-severe depression, that distance functions as a clinical asset rather than an inconvenience: it removes the client from the social and environmental triggers that maintain the depressive episode, and it makes on-site residential support during PHP a more practical option than a daily commute. RECO Health delivers depression treatment at PHP and IOP levels of care, with in-house psychiatry, measurement-based medication management, protocol-driven psychotherapy, and same-campus access to interventional options when standard treatment falls short.

Diagnostic formulation and severity staging

Every intake at RECO begins with a DSM-5-TR-based diagnostic formulation rather than a symptom checklist. The initial evaluation is structured to distinguish major depressive disorder from persistent depressive disorder, bipolar depression, adjustment disorder with depressed mood, and depression secondary to a general medical condition or substance use. That distinction matters clinically — starting an SSRI in an unrecognized bipolar II presentation without a mood stabilizer is a common iatrogenic pathway to a mixed or hypomanic episode.

Severity is anchored to the PHQ-9. Scores of 20 or higher indicate severe depression and generally trigger consideration of PHP rather than IOP. The C-SSRS captures suicidal ideation, plan, intent, and prior behavior at every visit. Where clinically indicated, the intake psychiatrist orders a thyroid panel with TSH reflex, vitamin B12, folate, and 25-hydroxy vitamin D — untreated hypothyroidism, B12 deficiency, and severe vitamin D deficiency present as depression in a meaningful minority of adult intakes.

Treatment intensity is then matched to severity. Clients with acute suicidal ideation, functional collapse, or PHQ-9 above 20 are staged for PHP with residential support in Delray Beach. Moderate presentations enter IOP three days per week. For Miami clients, that staging conversation happens before the drive up — no one should make the trip only to learn the recommended level of care does not match the presentation.

Pharmacology sequenced by evidence, not habit

First-line pharmacotherapy for major depression at RECO is an SSRI — typically sertraline titrated to 100-200 mg, or escitalopram to 20 mg — or an SNRI such as venlafaxine XR to 225 mg or duloxetine to 60 mg. Selection is based on prior response, side-effect profile, and comorbidity, particularly comorbid anxiety, chronic pain, or persistent fatigue. Each trial runs 4-6 weeks at a therapeutic dose before it is called adequate; under-dosing and under-duration are the two most common reasons for a labeled “treatment failure” that was never an actual treatment.

Partial responders — a PHQ-9 reduction of 25-50% — are augmented before the antidepressant is switched. Aripiprazole 2-5 mg, lithium 600-900 mg titrated to a therapeutic serum level, and bupropion XL 300 mg are the three augmentation strategies with the strongest STAR*D and CO-MED evidence base. Quetiapine XR is reserved for cases with prominent insomnia or comorbid anxiety where its metabolic side-effect burden is clinically justified. Switching to a different class happens when there is essentially no response, not partial response.

Every medication decision is documented alongside the PHQ-9 trajectory. That is what measurement-based care means in practice: the clinician reviews the score before the visit, the client sees the score during the visit, and neither adjusts the plan on clinical impression alone. Treatment-resistant depression — two failed adequate trials — triggers the escalation pathway rather than a fifth antidepressant.

Behavioral therapy modalities with evidence for depression

Depression treatment at RECO uses protocol-driven psychotherapy with published evidence for depression specifically, not a loose blend of supportive counseling. Cognitive Behavioral Therapy for depression (Beck protocol) targets cognitive distortions and behavioral withdrawal over 16-20 structured sessions. Behavioral Activation is often layered in first for clients in the deepest anhedonic phase — restoring rewarding and mastery activities before the client has the cognitive bandwidth for thought-record work.

Interpersonal Therapy addresses the four problem areas empirically linked to depressive episodes: grief, role transition, interpersonal dispute, and interpersonal deficit. For clients whose depression is trauma-linked, Cognitive Processing Therapy or EMDR is layered in once the client has stabilized enough to tolerate trauma processing safely. Acceptance and Commitment Therapy is used where depression is entangled with values-based avoidance, and Motivational Interviewing supports engagement in clients with ambivalence about treatment or medication adherence.

RECO’s therapists run these modalities to protocol under weekly clinical review. That review checks whether the plan on paper is still the plan being delivered in the room — a common failure mode in outpatient depression care is drift from evidence-based protocol into supportive counseling that neither client, therapist, nor referring psychiatrist explicitly notices until the PHQ-9 stalls.

Escalation pathway when medication and therapy are not enough

Roughly a third of clients with major depression will not achieve remission after two adequate antidepressant trials. RECO’s escalation pathway is defined at intake, not negotiated at the point of drift. For insurance-eligible treatment-resistant depression, rTMS runs the standard FDA-cleared protocol — 10 Hz stimulation over the left dorsolateral prefrontal cortex, 3000 pulses per session at 120% of motor threshold, five days per week over six weeks for a total of 36 sessions.

IV ketamine is used when suicidality or acute functional collapse will not tolerate the six-week rTMS build. The induction protocol is 0.5 mg/kg over 40 minutes, six infusions across two to three weeks, with maintenance dosing driven by PHQ-9 response and duration of effect. Esketamine (Spravato) is available where a REMS-monitored intranasal protocol is preferred — often driven by insurance policy rather than clinical preference, since both routes act primarily through NMDA-receptor antagonism.

Escalation happens on a schedule, not after months of drift. The treatment plan specifies, at admission, what happens if the first pharmacotherapy trial fails, what happens if augmentation fails, and what the neurostimulation or ketamine pathway looks like. Miami clients access the same escalation options — the drive from Coral Gables is not a barrier because most interventional visits are consolidated during the PHP or IOP stay in Delray Beach.

What to expect on the first visit from Miami

Most Miami clients arrive at the Delray Beach campus between 8 and 9 AM after driving up I-95. The first day is a full psychiatric evaluation with the attending psychiatrist, a therapy intake with the assigned primary therapist, and a case-management conversation covering housing, FMLA paperwork, and transportation for weekend passes and family sessions. Assessment tools completed at intake include the PHQ-9, GAD-7, C-SSRS, AUDIT, DAST-10, and — where substance use is present — CIWA or COWS to assess withdrawal risk.

Clients from Brickell, Aventura, Coconut Grove, or Pinecrest are typically advised to arrive with a two-week bag on the assumption PHP may be recommended. That avoids a second round trip if a higher acuity level of care is warranted after the evaluation. When IOP is the appropriate level of care, admissions coordinates a schedule that works around the drive from Miami-Dade.

Insurance and admissions from Miami

RECO Health is in-network with the commercial plans most commonly held by Miami-Dade residents: Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Verification of benefits runs during the first admissions call, and admissions returns a specific out-of-pocket estimate — deductible remaining, coinsurance percentage, and expected daily rate at the recommended level of care — before the client commits to the drive up. That estimate is written, not verbal.

If the recommended level of care is not covered outright, admissions works the appeal in parallel with a step-down clinical plan so treatment does not stall while insurance is negotiated. Same-day admission from Miami is often possible when acuity warrants it — the clinical intake team runs on a schedule that accommodates a mid-morning arrival from Miami-Dade.

Serving residents of: Brickell, Coral Gables, Coconut Grove, Aventura, Pinecrest.